Header

UZH-Logo

Maintenance Infos

Human papillomavirus antibody response following highly active antiretroviral therapy initiation among men who have sex with men


Combes, J D; Clifford, G M; Egger, M; Cavassini, M; Hirsch, H; Hauser, C; Calmy, A; Schmid, P; Bernasconi, E; Gunthard, H F; Franceschi, S; Waterboer, T; Scherrer, A U (2016). Human papillomavirus antibody response following highly active antiretroviral therapy initiation among men who have sex with men. AIDS, 31(4):561-569.

Abstract

Objective: To describe effects of highly active antiretroviral therapy (HAART) on high-risk (HR) human papillomavirus (HPV) antibody response in HIV-positive men who have sex with men (MSM), and the meaning of this response for subsequent HPV-related cancer risk.
Design: Prospective seroepidemiological study of 281 HIV-positive MSM initiating HAART between 1995 and 2004 in the Swiss HIV Cohort Study.
Methods: For each individual, two serum samples, one at HAART initiation (pre-HAART) and another 24 months later (post-HAART), were tested for L1 antibodies to HPV6, 11, 16, 18, 31, 33, 35, 45, 52 and 58, as well as HPV16-E6 antibodies, using a multiplex serology assay. Identification of HPV-related cancer included data linkage with Swiss cancer registries.
Results: Pre-HAART, 45.2% were seropositive for any high-risk (HR)-HPV-L1 and 32.4% for HPV16-L1. Sexual intercourse during the last six months was the only evaluated factor associated with L1 seropositivity pre-HAART. Seropositivity increased post-HAART to 60.5% for any HR-HPV-L1 (prevalence ratio versus pre-HAART = 1.34, 95% confidence interval (CI) 1.14-1.57), and 48.0% for HPV16-L1 (prevalence ratio versus pre-HAART = 1.48, 95% CI 1.20-1.83), and seroconversion was significantly associated with both lower CD4+ count and CD4+/CD8+ ratio (p < 0.01). Only one individual was HPV16-E6 seropositive pre-HAART, but two more seroconverted post-HAART. Anal cancer incidence among the three HPV16-E6-positives post-HAART was significantly increased compared to HPV16-E6-negatives (incidence rate ratio = 63.1, 95% CI 1.1-1211).
Conclusion: HAART-related immune reconstitution increases HPV-specific antibody responses, which may discriminate future anal cancer risk in this high-risk population.

Abstract

Objective: To describe effects of highly active antiretroviral therapy (HAART) on high-risk (HR) human papillomavirus (HPV) antibody response in HIV-positive men who have sex with men (MSM), and the meaning of this response for subsequent HPV-related cancer risk.
Design: Prospective seroepidemiological study of 281 HIV-positive MSM initiating HAART between 1995 and 2004 in the Swiss HIV Cohort Study.
Methods: For each individual, two serum samples, one at HAART initiation (pre-HAART) and another 24 months later (post-HAART), were tested for L1 antibodies to HPV6, 11, 16, 18, 31, 33, 35, 45, 52 and 58, as well as HPV16-E6 antibodies, using a multiplex serology assay. Identification of HPV-related cancer included data linkage with Swiss cancer registries.
Results: Pre-HAART, 45.2% were seropositive for any high-risk (HR)-HPV-L1 and 32.4% for HPV16-L1. Sexual intercourse during the last six months was the only evaluated factor associated with L1 seropositivity pre-HAART. Seropositivity increased post-HAART to 60.5% for any HR-HPV-L1 (prevalence ratio versus pre-HAART = 1.34, 95% confidence interval (CI) 1.14-1.57), and 48.0% for HPV16-L1 (prevalence ratio versus pre-HAART = 1.48, 95% CI 1.20-1.83), and seroconversion was significantly associated with both lower CD4+ count and CD4+/CD8+ ratio (p < 0.01). Only one individual was HPV16-E6 seropositive pre-HAART, but two more seroconverted post-HAART. Anal cancer incidence among the three HPV16-E6-positives post-HAART was significantly increased compared to HPV16-E6-negatives (incidence rate ratio = 63.1, 95% CI 1.1-1211).
Conclusion: HAART-related immune reconstitution increases HPV-specific antibody responses, which may discriminate future anal cancer risk in this high-risk population.

Statistics

Altmetrics

Downloads

0 downloads since deposited on 25 Jan 2017
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Uncontrolled Keywords:HPV, serology, HIV, HAART, anal cancer
Language:English
Date:3 December 2016
Deposited On:25 Jan 2017 11:48
Last Modified:19 Mar 2017 06:21
Publisher:Lippincott Williams & Wilkins
ISSN:0269-9370
Funders:Swiss HIV Cohort Study (SHCS-project 495), Swiss National Science Foundation (Grant 148522), OncoSuisse (ICP OCS 01355-03-2003, K FS-02478-08-2009).
Publisher DOI:https://doi.org/10.1097/QAD.0000000000001354

Download

Preview Icon on Download
Content: Published Version
Filetype: PDF - Registered users only until 20 February 2018
Size: 479kB
View at publisher
Embargo till: 2018-02-20